Literature DB >> 11817442

Erythromycin as a gastrointestinal prokinetic agent.

C Bradley1.   

Abstract

Erythromycin is a potent stimulator of gastrointestinal (GI) motility and can be a useful agent to treat GI stasis in patients who are critically ill. However, it is not licensed for this indication and has serious drug interactions which may limit its utility. Erythromycin derivatives which lack antibiotic activity have been developed but are still undergoing pre-marketing investigations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817442     DOI: 10.1054/iccn.2000.1566

Source DB:  PubMed          Journal:  Intensive Crit Care Nurs        ISSN: 0964-3397            Impact factor:   3.072


  2 in total

1.  Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study.

Authors:  Hans F Berg; Jeroen H T Tjhie; Gert-Jan Scheffer; Marcel F Peeters; Peter H J van Keulen; Jan A J W Kluytmans; Ellen E Stobberingh
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 2.  Microbial drug discovery: 80 years of progress.

Authors:  Arnold L Demain; Sergio Sanchez
Journal:  J Antibiot (Tokyo)       Date:  2009-01-09       Impact factor: 2.649

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.